Results 111 to 120 of about 623,894 (355)

Histological Transformation to Small Cell Carcinoma of an Adenosquamous Carcinoma of the Lung With Epidermal Growth Factor Receptor Mutation in Exons 20 and 21 After Treatment With Erlotinib: Case Report

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2019
Lung carcinoma currently represents 1 of the leading causes of death from cancer worldwide and regionally. The molecular identification of sensitive mutations of targeted treatment have changed the strategies of pharmacologic management in non-small cell
Liliana Fernández-Trujillo, Laura Tapia, Marcela Vallejo, Marisol Aguirre, Juliana Lores, Luz F Sua   +5 more
doaj   +1 more source

Basic and Clinical Aspects of Non-neuronal Acetylcholine: Expression of Non-neuronal Acetylcholine in Lung Cancer Provides a New Target for Cancer

Journal of Pharmacological Sciences, 2008
Lung cancer is the leading cause of cancer death worldwide and new treatment strategies are clearly needed. The recent discovery that lung and other cancers synthesize and secrete acetylcholine (ACh) which acts as an autocrine growth factor suggests that
Therapy Pingfang Song, Eliot R. Spindel
doaj   +1 more source

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]

, 2007
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross, Pavlakis, Nick, Stordal, Britta   +2 more
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India

Lung India, 2014
Background: Lung cancer is a highly aggressive malignancy causing high morbidity and mortality. An increasing incidence of lung cancer has been observed in India.
Shanmugapriya Shankar, Vijayalakshmi Thanasekaran, T Dhanasekar, Prathiba Duvooru   +3 more
doaj   +1 more source

Data from <i>MET</i> Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis

, 2023
Joanna H. Tong, Sai F. Yeung, Anthony W.H. Chan, Lau Y. Chung, Shuk L. Chau, Raymond Wai Ming Lung, Carol Y. Tong, Chit Chow, Edith K.Y. Tin, Yau H. Yu, Hui Li, Yi Pan, Wing P. Chak, Calvin S.H. Ng, Tony Mok, Ka‐Fai To   +15 more
openalex   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

FEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel, Caroline Wozniak, Aya Sabri, Ben Haddad, Brooke Lopo, Alvaro Cobos, Sarah Sarofim, Jeffrey Guthrie, Deborah Heyl, Hedeel Guy Evans   +9 more
wiley   +1 more source

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. [PDF]

, 2017
Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic ...
Beckman, Robert A., Boca, Simina M., Brody, Jonathan R., Madhavan, Subha, Marshall, John L., Pishvaian, Michael J., Rao, Shruti, Riazi, Shahla, Yabar, Cinthya S.   +8 more
core   +1 more source

Long non-coding RNA SOX2OT: Expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis [PDF]

, 2015
SOX2 overlapping transcript (SOX2OT) is a long non-coding RNA which harbors one of the major regulators of pluripotency, SOX2 gene, in its intronic region.
Jazi, M.S., Mowla, S.J., Samaei, N.M., Shahryari, A.   +3 more
core   +1 more source

bcl-2 Protein in Non-Small-Cell Lung Carcinoma

New England Journal of Medicine, 1993
The proto-oncogene bcl-2 encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma.
Pezzella, F, Turley, H, Kuzu, I, Tungekar, M, Dunnill, MS, Pierce, C, Harris, A, Gatter, K, Mason, D   +8 more
openaire   +3 more sources